Propanc Biopharma, Inc. (PPCB)

Propanc Biopharma Balance Sheet

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Cash & Equivalents	0.05	0.02	0.01	0	0	0.07
Cash & Short-Term Investments	0.05	0.02	0.01	0	0	0.07
Cash Growth	715.82%	109.86%	147.04%	80.36%	-96.64%	2698.96%
Other Receivables	0	0	0	0	0	0
Receivables	0	0	0	0	0	0
Prepaid Expenses	9.68	0	0.01	0.01	-	-
Total Current Assets	9.74	0.03	0.02	0.02	0.01	0.07
Property, Plant & Equipment	0	0.02	0.04	0.06	0	0.03
Long-Term Deferred Charges	0.09	0.03	-	-	-	-
Other Long-Term Assets	12.7	0	0	0	0	0
Total Assets	22.53	0.07	0.06	0.08	0.01	0.1
Accounts Payable	1.12	1.21	0.97	0.94	1	0.84
Accrued Expenses	1.87	1.53	1.21	0.94	1.31	1.06
Short-Term Debt	1.15	0.87	0.51	0.98	0.68	1.61
Current Portion of Leases	0	0.02	0.02	0.02	-	0.03
Other Current Liabilities	0.19	0.16	0.45	0.18	0.09	0.21
Total Current Liabilities	4.34	3.79	3.16	3.06	3.08	3.74
Long-Term Debt	0.09	0.06	-	-	-	-
Long-Term Leases	-	-	0.02	0.04	-	-
Total Liabilities	4.44	3.85	3.18	3.11	3.08	3.74
Common Stock	0.01	0.48	0.01	0	0.01	0
Additional Paid-In Capital	138.21	61.22	60.31	57.36	54.07	50.91
Retained Earnings	-121.55	-66.7	-64.68	-61.56	-58.2	-55.78
Treasury Stock	-0.05	-0.05	-0.05	-0.05	-0.05	-0.05
Comprehensive Income & Other	1.46	1.27	1.29	1.21	1.09	1.27
Total Common Equity	18.09	-3.78	-3.12	-3.03	-3.07	-3.65
Shareholders' Equity	18.09	-3.78	-3.12	-3.02	-3.07	-3.64
Total Liabilities & Equity	22.53	0.07	0.06	0.08	0.01	0.1
Total Debt	1.25	0.95	0.55	1.04	0.68	1.63
Net Cash (Debt)	-1.2	-0.93	-0.54	-1.04	-0.68	-1.57
Filing Date Shares Outstanding	11.61	0.01	-	-	-	-
Working Capital	5.39	-3.77	-3.14	-3.05	-3.07	-3.67
Tangible Book Value	18.09	-3.78	-3.12	-3.03	-3.07	-3.65
Machinery	-	0.03	0.03	0.03	0.03	0.03

Source: S&P Global Market Intelligence. Standard template. Financial Sources.